Cellosaurus HTC-C3 (CVCL_1295)

Cell line name HTC-C3
Synonyms HTC/C3; HTC C3; HTCC3
Accession CVCL_1295
Resource Identification Initiative To cite this cell line use: HTC-C3 (RRID:CVCL_1295)
Comments Doubling time: ~100 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Disease Thyroid gland undifferentiated (anaplastic) carcinoma (NCIt: C3878)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200; RCB

Markers:
AmelogeninX
CSF1PO11,12
D13S31710,12
D16S5399,12
D18S5114,17
D19S43314
D21S1129,30
D2S133817,23
D3S135816
D5S81811,12
D7S82011,12
D8S117912,14
FGA21,22
Penta D9
Penta E11,16
TH016,7
TPOX8,9
vWA14,15
Publications

PubMed=2196988; DOI=10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V
Enomoto T., Sugawa H., Inoue D., Miyamoto M., Kosugi S., Takahashi T., Kitamura N., Yamamoto I., Konishi J., Mori T., Imura H.
Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines.
Cancer 65:1971-1979(1990)

PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3
Satake S., Sugawara I., Watanabe M., Takami H.
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Cancer Lett. 116:33-39(1997)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections DSMZ; ACC-580
JCRB; JCRB0164
RCB; RCB0452
Cell line databases/resources CGH-DB; 58-1
Cosmic-CLP; 924151
GDSC; 924151
LINCS_LDP; LCL-1689
Ontologies CLO; CLO_0050946
Biological sample resources BioSample; SAMN01821636
BioSample; SAMN01821686
BioSample; SAMN03470940
Chemistry resources ChEMBL-Cells; CHEMBL3308747
ChEMBL-Targets; CHEMBL1075472
Gene expression databases GEO; GSM1669916
Polymorphism and mutation databases Cosmic; 924151
Cosmic; 2009524
Cosmic; 2054084
Cosmic; 2613249